Pharmacovigilance ICSR Intake, MedDRA Coding & Safety Narrative Automation
GxP Agents automates multi-channel adverse event intake, ICH E2B(R3) field extraction, MedDRA term coding, seriousness assessment support, and clinical case narrative drafting—reducing per-case processing time by up to 65% while safeguarding 7-day and 15-day expedited FDA/EMA reporting compliance.
How the Multi-Agent Workflow Executes
ICSR Intake Agent
Extracts patient, reporter, suspect drug, concomitant medication, and adverse event data from forms, emails, call transcripts, and literature.
Medical Terminology Agent
Maps verbatim reporter terms to current MedDRA LLT/PT hierarchies and WHODrug codes with explicit confidence thresholds.
Safety Narrative Agent
Evaluates IME/DME lists and IB/CCDS expectedness to flag 7/15-day expedited cases and generates a chronological clinical case narrative.
21 CFR Part 11 / GVP Medical Gate
Routes coded case and draft narrative to the safety specialist and medical reviewer for causality evaluation and e-signature.
Accountable Role: Drug Safety Physician / Qualified Person for Pharmacovigilance (QPPV)
Signature Meaning: Medical Review, Causality Assessment & Regulatory Expedited Submission Approval. Agents never execute autonomous GxP disposition or modify validated system-of-record state without human approval.
Legacy Manual Process vs. Validated GxP Agent Workflow
| Workflow Dimension | Legacy Manual Process | GxP Agent Validated Workflow |
|---|---|---|
| Case Intake & Data Entry | 45–90 minutes of manual transcription from PDFs, faxes, and emails into Argus/Vault | < 3 minutes automated E2B(R3) extraction with source-span highlighting |
| MedDRA & WHODrug Coding | Manual dictionary browsing; inter-coder variability across global hubs | Standardized MedDRA LLT/PT mapping with confidence routing to human coders |
| Clinical Narrative Writing | 30–60 minutes drafting chronological narratives from scratch | Structured, template-compliant narrative drafted in seconds with lab & dose tables |
FDA, EMA, ICH & GAMP 5 Controls Built In
Postmarketing Reporting of Adverse Drug & Biologic Experiences
Prioritizes serious and unexpected adverse events immediately at Day 0 intake to protect 15-day Alert Report timelines.
Management and Reporting of Adverse Reactions to Medicinal Products
Maintains complete auditability of case intake, duplicate detection, and QPPV oversight.
Electronic Transmission of Individual Case Safety Reports
Outputs schema-validated E2B(R3) data elements ready for EudraVigilance and FDA FAERS.
Production Evidence, Validation Guides & Deep Dives
Biotech Startup Completes FDA IND Submission 3 Months Ahead of Schedule
AI-assisted eCTD submission assembly and regulatory intelligence turned an 18-month timeline into 15
The Complete Guide to 21 CFR Part 11 Compliance for AI Systems
A practical framework for implementing AI tools within FDA-regulated environments. Covers electronic records, electronic signatures, audit trails, and validation strategies specific to AI/ML systems.
Related Regulatory & Architecture Articles
Frequently Asked Questions: PV & ICSR Case Automation
Does the AI determine causality or submit ICSRs directly to FDA FAERS or EudraVigilance?
No. Causality assessment, final seriousness/expectedness confirmation, and regulatory gateway transmission always require review and electronic signature by a qualified pharmacovigilance professional or Drug Safety Physician.
How are MedDRA dictionary version updates handled?
Semiannual MedDRA and WHODrug dictionary updates are managed under controlled configuration management with automated regression testing across a gold-standard validation set before promotion to production.